These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38265843)

  • 21. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
    Bouchard P; Wolf JP; Hajri S
    Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update].
    von Amsberg G; Thiele H; Merseburger A
    Urologe A; 2021 Nov; 60(11):1450-1457. PubMed ID: 34213627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk with androgen deprivation therapy.
    Rosenberg MT
    Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity.
    Tanriverdi F; Silveira LF; MacColl GS; Bouloux PM
    J Endocrinol; 2003 Mar; 176(3):293-304. PubMed ID: 12630914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study.
    Chan JSK; Lee YHA; Hui JMH; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
    Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):e376-e383. PubMed ID: 37031076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine.
    Saleh FL; Taylor HS
    F S Rep; 2023 Jun; 4(2 Suppl):83-87. PubMed ID: 37223759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-peptidic GnRH receptor antagonists.
    Armer RE; Smelt KH
    Curr Med Chem; 2004 Nov; 11(22):3017-28. PubMed ID: 15544487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation.
    Valsamakis G; Valtetsiotis K; Charmandari E; Lambrinoudaki I; Vlahos NF
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
    Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
    Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice.
    Lindzey J; Wetsel WC; Couse JF; Stoker T; Cooper R; Korach KS
    Endocrinology; 1998 Oct; 139(10):4092-101. PubMed ID: 9751487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
    J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.
    Maggi R; Cariboni AM; Marelli MM; Moretti RM; Andrè V; Marzagalli M; Limonta P
    Hum Reprod Update; 2016 Apr; 22(3):358-81. PubMed ID: 26715597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Toxicity of Androgen Deprivation Therapy.
    Boland J; Choi W; Lee M; Lin J
    Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH antagonists in the treatment of advanced prostate cancer.
    Pommerville PJ; de Boer JG
    Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
    Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
    Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.